Substance and claimed effects

Adult ADHD is the persistence of attention-deficit/hyperactivity disorder into adulthood: a neurodevelopmental condition rooted in dysregulated catecholamine (dopamine + norepinephrine) signalling in fronto-striatal and fronto-parietal networks, present from childhood (DSM-5 requires several symptoms before age 12) and continuing to cause functional impairment after age 18. Adult prevalence is ~2.5-4.4% in nationally representative samples Kessler et al. 2006; the World Federation consensus revises that upward to ~2.5% in adults using strict DSM-5 thresholds, with childhood-onset ADHD persisting in roughly 50-65% of cases into adulthood Faraone et al. 2021. This entry covers the adult presentation across the dimensions named in the brief: diagnostic pathway, treatment options (pharmacological + psychosocial), and consequences for attention/executive function, mood and emotional regulation, work and academic performance, relationships, sleep, substance use, accident risk, and all-cause mortality. Heritability is ~74% across 37 twin studies Faraone and Larsson 2019, making ADHD one of the most heritable psychiatric conditions; this entry treats it as a real, persistent, treatable biological condition rather than a behavioural choice.

Evidence by addressing question

Mechanism

Science. ADHD reflects under-activation of catecholamine signalling in prefrontal cortex (PFC), anterior cingulate, and striatum. Dopamine transporter (DAT) density and binding patterns differ in ADHD brains, and stimulant medications (methylphenidate, amphetamines) raise synaptic dopamine and norepinephrine in PFC by blocking reuptake transporters (methylphenidate) or both blocking reuptake and promoting release (amphetamines). Atomoxetine is a selective norepinephrine reuptake inhibitor and works through the same prefrontal-norepinephrine pathway without the dopaminergic reward-circuit effects. Guanfacine and clonidine are alpha-2A adrenergic agonists that strengthen PFC network connectivity by mimicking norepinephrine on post-synaptic receptors Faraone et al. 2021.

Mechanism (executive function). The clinical phenotype maps onto deficits in working memory, response inhibition, sustained attention, time perception, and emotional regulation — all PFC-dependent executive functions. Adults with ADHD show consistent group-level differences in fMRI activation of fronto-striatal circuits during inhibition and attention tasks, though no neuroimaging marker is diagnostically useful at the individual level Faraone et al. 2021.

Mechanism (genetics). Twin-study heritability ~74%; genome-wide association studies have identified multiple common variants of small effect plus rare copy-number variants, with substantial genetic overlap with autism, major depression, and educational attainment Faraone and Larsson 2019. There is no single ADHD gene; it is polygenic, like height or intelligence.

Evidence

Science (medication efficacy). The 2018 Cortese network meta-analysis pooled 133 randomized trials including 10,296 adults: in adults, amphetamines were the most efficacious medication on clinician-rated symptoms (standardized mean difference ~0.79 vs placebo) and most acceptable; methylphenidate was efficacious but with smaller effect size in adults than in children; atomoxetine, modafinil, and bupropion showed smaller but real effects. The reviewers' first-line recommendation for adults is amphetamines, with methylphenidate as alternative Cortese et al. 2018. NICE NG87 (2018, updated 2019) recommends methylphenidate first-line in adults with lisdexamfetamine (an amphetamine prodrug) as alternative, reflecting differing regulatory and abuse-potential considerations across jurisdictions NICE 2019.

Science (psychosocial). Two landmark RCTs established CBT for adult ADHD as an evidence-based add-on to medication: Safren et al. 2010 randomized 86 medication-treated adults with persistent symptoms to CBT vs relaxation+education; CBT produced larger reductions on both self-rated and blinded-rater ADHD symptom scales, with effects maintained at 12 months. Solanto et al. 2010 tested a 12-week metacognitive group therapy targeting time management, organization, and planning in 88 adults with ADHD; the treatment arm showed significantly greater symptom reduction than supportive psychotherapy control, with NNT of ~3 for symptom remission.

Science (mortality and accidents). The Dalsgaard 1.92-million-person Danish cohort showed adults with ADHD have ~2x all-cause mortality compared with peers (mortality rate ratio 2.07, 95% CI 1.70-2.50), driven primarily by unnatural causes — accidents, suicide, overdose — and the effect is larger in adults than children Dalsgaard et al. 2015. The follow-up Sun et al. 2019 showed adult-onset psychiatric comorbidity (substance use disorder in particular) further multiplied the mortality risk: in adults with ADHD, the hazard ratio for premature death was 4.64 (95% CI 4.11-5.25) compared with the population without ADHD. Chang's Swedish-registry study showed adults with ADHD had higher rates of serious transport accidents than peers; medication treatment reduced this risk by 58% in men and 42% in women, established via within-person comparison of medicated vs unmedicated periods in the same individuals Chang et al. 2014.

Science (criminality, substance use). Lichtenstein et al. 2012 followed 25,656 Swedish adults with ADHD and found medication periods were associated with 32% lower criminal conviction rates in men and 41% lower in women, again via within-person comparison. Chang et al. 2014b showed stimulant treatment was associated with 31% lower substance-abuse risk three years later — counter to the worry that prescribing stimulants to people prone to addiction would worsen outcomes.

Practice / clinical consensus. The World Federation International Consensus Statement synthesized 208 evidence-based conclusions, including: ADHD is a valid disorder in adults, persists in over half of childhood cases, is associated with substantial functional impairment and mortality, and is effectively treated by stimulants and non-stimulants with effect sizes larger than most psychiatric medications Faraone et al. 2021. NICE NG87 and the American Professional Society of ADHD and Related Disorders both endorse stimulant medication as first-line for adults, with CBT as evidence-based adjunct NICE 2019.

Audience and population variability

Science (women). Women with ADHD are systematically underdiagnosed in childhood because the predominantly-inattentive presentation (without overt hyperactivity) gets missed; the female-to-male ratio in clinical childhood samples is ~1:3-4, while in adult population samples it approaches 1:1, suggesting late catch-up diagnosis in women Faraone et al. 2021. Hormonal cycling interacts with symptoms — many women report symptom worsening pre-menstrually and around perimenopause, though the trial evidence is preliminary.

Mechanism (presentation drift). Hyperactivity tends to attenuate or internalize with age (overt fidgeting → internal restlessness, racing thoughts); the inattentive and executive-dysfunction features persist or worsen as adult life demands more self-organization. Many adults diagnosed late were never "obviously" hyperactive children — they were inattentive or compensated with high IQ until the supportive scaffolding of school ended Faraone et al. 2021.

Misconceptions

Science / community. The two most common misconceptions: (1) "ADHD is over-diagnosed and not a real condition" — contradicted by the ~74% heritability, consistent neuroimaging signatures, and large mortality / accident / employment-outcome differences in untreated cases Faraone et al. 2021 Faraone and Larsson 2019; (2) "Stimulants cause addiction" — contradicted by the substance-abuse and criminality follow-ups Chang et al. 2014b Lichtenstein et al. 2012. A subtler misconception: that ADHD is primarily about attention. The core deficit is executive function and self-regulation; attention is one symptom domain among several.

Protocol

Practice / clinical consensus. Diagnosis requires a clinician trained in adult ADHD assessment. The DSM-5 standard requires ≥5 symptoms of inattention and/or hyperactivity-impulsivity (vs 6 in children), present in two or more settings, causing functional impairment, with several symptoms documented before age 12, not better explained by another condition. Structured instruments (DIVA-5, ACE+, ASRS) standardize the interview; collateral history from a parent or partner is recommended where possible NICE 2019.

Practice (medication). First-line in most jurisdictions is a stimulant: methylphenidate (immediate-release titrated through long-acting Concerta/Ritalin LA/Medikinet XL) or amphetamine (Adderall XR, dextroamphetamine, lisdexamfetamine/Vyvanse). Titration starts low (5-10 mg methylphenidate equivalent or 10-20 mg lisdexamfetamine) and adjusts weekly to therapeutic response. Therapeutic dose range is wide (Cortese mean ~36 mg/day methylphenidate equivalent; lisdexamfetamine 30-70 mg/day) Cortese et al. 2018. Non-stimulants — atomoxetine (40-100 mg/day, 4-6 weeks to full effect), guanfacine ER, viloxazine — are second-line, used when stimulants are contraindicated (cardiovascular concerns, substance-use risk) or insufficient. Cardiovascular screening (blood pressure, history, examination; ECG only if indicated) before starting; blood pressure and pulse monitored at follow-up NICE 2019.

Practice (psychosocial). CBT specifically adapted for adult ADHD — covering time management, organization, anti-procrastination, and emotional regulation — is the evidence-based adjunct, especially for residual symptoms after medication titration Safren et al. 2010 Solanto et al. 2010. Coaching, structured external systems (calendar, body-doubling, reminder apps), and accommodation in education or work also have a place.

Contraindications

Science / practice. Stimulants raise heart rate and blood pressure modestly (a few mmHg, a few bpm); absolute contraindications are serious structural cardiac disease, recent MI, severe arrhythmia, uncontrolled hypertension, and pheochromocytoma. Active eating disorder is a relative contraindication (stimulants suppress appetite). Active substance use disorder is a relative contraindication for short-acting stimulants but not for long-acting formulations or lisdexamfetamine (which has lower abuse potential due to its prodrug pharmacokinetics). Bipolar disorder requires mood-stabilizer coverage first. Pregnancy: methylphenidate and amphetamines are not first-choice; risk-benefit must be reconsidered. ADHD treatment in untreated obstructive sleep apnea is wasted — sleep apnea independently produces ADHD-like inattention NICE 2019 Faraone et al. 2021.

Failure modes

Practice / community. The most common reasons adult ADHD treatment "doesn't work": (1) under-dosing — adults often need higher milligram doses than they were started on; the prescriber stopped at the first non-trivial response rather than titrating to optimal Cortese et al. 2018; (2) sleep disruption from stimulants — typically a too-late afternoon dose, partially fixable by morning-only dosing or formulation change; (3) untreated sleep disorder — particularly delayed sleep phase syndrome (DSPS), present in ~73-78% of adults with ADHD Bijlenga et al. 2019, and undiagnosed obstructive sleep apnea; (4) untreated comorbid anxiety or depression; (5) misdiagnosis — autism, bipolar II, complex PTSD, and high-functioning learning disabilities can present with overlapping symptoms; (6) telehealth-only diagnosis with a 30-minute intake and no collateral, leading to inaccurate diagnoses in both directions.

Stakes and payoff

Science (untreated trajectory). The accident, mortality, and criminality data make this an unusually grim "untreated" picture by mental-health standards. Adults with untreated ADHD have ~2x all-cause mortality Dalsgaard et al. 2015, ~4.6x premature death risk when comorbidity is included Sun et al. 2019, ~2x rate of serious traffic accidents (reducible 50%+ on medication) Chang et al. 2014, ~30-40% higher conviction rates (reducible on medication) Lichtenstein et al. 2012, and substantially elevated rates of substance-use disorder, divorce, job loss, unplanned pregnancy, and bankruptcy. These are population-level effects, not individual prophecies — the typical reader is much closer to the median than to the catastrophic tail.

Science (treated trajectory). Stimulant medication produces a Cortese-pooled standardized mean difference of ~0.79 on clinician-rated symptoms — among the larger effect sizes in psychiatry, dwarfing typical antidepressant or anxiolytic effect sizes (~0.3) Cortese et al. 2018. Functional outcome data are weaker than symptom-reduction data (most trials are weeks to months, not years), but registry studies link medication periods to lower accident, criminal, and substance-use rates within the same individuals.

History

ADHD was first conceptualized as a childhood disorder ("minimal brain dysfunction" in the 1960s, attention deficit disorder in DSM-III 1980). The persistence into adulthood was formally acknowledged in DSM-IV (1994), with adult diagnostic criteria refined in DSM-5 (2013) — most importantly, the lowered symptom-count threshold for adults (5 vs 6) and the raised age-of-onset criterion (from age 7 to age 12). The shift in clinical recognition from "kids grow out of it" to "most cases persist" took roughly two decades of longitudinal cohort follow-ups Faraone et al. 2021.

Credibility range

Optimist case. Adult ADHD is a real, biologically grounded, highly heritable condition with one of the strongest evidence bases for medication in all of psychiatry. The Cortese network meta-analysis pools data from over 10,000 adults across 133 trials; the effect sizes for stimulants in adults are large (SMD ~0.79) by any psychiatric standard Cortese et al. 2018. Registry studies in Sweden and Denmark establish causal-ish within-person evidence that medication periods reduce accidents, crime, and substance abuse Chang et al. 2014 Lichtenstein et al. 2012 Chang et al. 2014b. Mortality is ~2x untreated, comparable to moderate cardiovascular disease, and treatment plausibly attenuates the unnatural-cause excess. Underdiagnosis remains the bigger error — most adults with ADHD are still not in treatment, women and people of colour disproportionately so. The condition is also probably under-treated even after diagnosis, since titration commonly stops short of optimal dose.

Skeptic case. Adult ADHD diagnosis is a moving target. The DSM-5 lowered the adult symptom threshold (5 vs 6) and raised the age-of-onset criterion (12 vs 7), mechanically expanding the population that qualifies. Telehealth-only ADHD clinics in the US have grown rapidly with thin diagnostic processes; the FTC-investigated business models incentivize prescribing. Some longitudinal data suggest "late-onset adult ADHD" cases (no documented childhood symptoms) may largely reflect other conditions (anxiety, sleep deficit, depression) mislabeled. Industry funding pervades the consensus literature — many of the Faraone consensus authors disclose pharmaceutical relationships. Effect sizes from Cortese are based largely on short-term symptom scales, not long-term functional outcomes; the registry studies are confounded by indication (the patient who fills their prescription is different from one who doesn't). Stimulants do have abuse potential, do cause cardiovascular effects, do suppress appetite and disturb sleep; the long-term safety dataset over decades is limited.

Author's call. The core science is solid: adult ADHD is real, highly heritable, mechanistically grounded, and has the largest medication effect sizes in psychiatry. The mortality and accident data make this a high-stakes condition to leave untreated, comparable to moderate cardiovascular risk. The diagnostic controversy is real and concentrated at the diagnostic edge — telehealth shortcuts, expanded criteria, late-onset claims — not at the core syndrome. A proper assessment by a clinician trained in adult ADHD, ideally with collateral history, remains the gate; the catalogue's action should be decide (with a clinician) rather than do (self-implement). Stimulant safety is good enough that under-treatment is plausibly the larger population error — but this individual user should get a thorough evaluation, not a checkbox.

Stakeholders and incentives

• Pharmaceutical industry. Major makers of branded stimulants (Takeda/Vyvanse, formerly Shire) and non-stimulants fund a significant share of trials and educational materials. Influence is visible in dosing-comparison studies and marketing of long-acting formulations.
• Telehealth ADHD clinics. US-specific phenomenon (Cerebral, Done, Klarity) that exploded during 2020-2022 controlled-substance prescribing relaxation; FTC and DOJ have investigated several. Incentive structures push toward diagnosis and prescription with minimal time.
• Adult ADHD advocacy organizations (CHADD, ADDA, AADD). Advance recognition, destigmatization, and access to care. Some industry funding; positions are generally aligned with mainstream science.
• Adult ADHD community on social media (TikTok, Reddit, YouTube). Significant influence on which adults seek evaluation. Drives both legitimate self-recognition (especially among undiagnosed women) and over-identification with normal life difficulties.
• Skeptical voices. Critical psychiatrists (e.g., Joanna Moncrieff in the UK, parts of the Critical Psychiatry Network), some general psychiatrists who worry about over-diagnosis, the Cochrane review group on methylphenidate which has flagged trial-quality concerns. Counter-incentive: scientific rigor, concern about long-term safety data.
• Regulators (FDA, DEA, MHRA, EMA). DEA scheduling of stimulants as Schedule II controls dispensing; this drives the controlled-substance refill burden and supply shortages that began in late 2022. NICE in the UK takes a more conservative line than US clinical practice.

Population variability

• Sex. Childhood diagnosis is heavily male-skewed (~3-4:1); adult clinical samples approach parity, suggesting late catch-up in women whose inattentive presentation was missed. Hormonal cycling effects on symptoms are reported but lightly studied Faraone et al. 2021.
• Age. Hyperactivity attenuates with age; inattention and executive-function deficits persist or worsen. The 60+ population has been less studied but treatment efficacy appears retained, with more cardiovascular caution.
• Comorbidity. ~80% of adults with ADHD have at least one comorbid condition: anxiety disorders (50%), major depression (30-40%), substance-use disorder (15-25%), bipolar spectrum (5-10%), autism spectrum (15-25%), learning disabilities. Sleep disorders — particularly delayed sleep phase syndrome — present in 73-78% Bijlenga et al. 2019.
• Race and socioeconomic status. US diagnostic rates lag in Black and Hispanic populations relative to white; access to evaluation and stimulants both differ. The science of the condition does not differ by race; the diagnostic and treatment pipeline does.
• Genetic. First-degree relatives of probands have 5-10x relative risk Faraone and Larsson 2019; family history strengthens diagnostic confidence.

Knowledge gaps

• Long-term outcomes from medication. Most RCT data is weeks to months. Registry studies establish association with reduced accidents and crime but cannot establish that decades of stimulant use protect functional outcomes vs years of medication-then-stop. The trials needed to settle this would be impractical.
• "Adult-onset" ADHD. Some longitudinal cohorts (Dunedin, E-Risk) find adults meeting ADHD criteria who showed no documented childhood symptoms — these may represent measurement error, late-emerging cases, or other conditions misclassified. The DSM-5 requires childhood symptoms but documentation is often retrospective.
• Female-specific data. Hormonal modulation of symptoms (menstrual cycle, perimenopause, postpartum) is patient-reported but lightly trialled. Stimulant dosing in women is largely extrapolated from male-majority trial populations.
• Cardiovascular long-term. Stimulants cause small mean blood-pressure and heart-rate elevations; the long-term population cardiovascular impact at scale is not fully settled, though large observational studies have not shown a meaningful event-rate signal.
• Optimal medication holidays vs continuous treatment. Unsettled. Weekend / vacation drug holidays are common but not formally trialled in adults.
• Psychosocial-treatment durability. CBT trials are 8-15 sessions with up-to-12-month follow-up. Whether the gains hold at 5 years is unknown.

Scope decisions. The brief named diagnostic pathways, treatment options, and effects on attention, executive function, mood, work performance, relationships, and accident risk. All are covered. Attention and executive function are the load-bearing thread (mechanism, evidence, payoff); work / relationships / accident risk live in stakes and payoff via felt-experience prose anchored to the Swedish-registry data Chang et al. 2014 and Lichtenstein et al. 2012. Mood is covered in payoff and failure-modes (comorbid depression/anxiety unmasking when ADHD is treated). No silent narrowing.

What was excluded and why.

• Childhood ADHD. Different population, different diagnostic process, different treatment-tracking logistics. Flagged as a separate-entry candidate.
• Specific medication-by-medication deep dives. The taxonomy (stimulant classes, lisdexamfetamine prodrug pharmacokinetics, atomoxetine slow onset) is in protocol; head-to-head comparison of branded formulations is clinician territory.
• ADHD coaching as a standalone modality. Mentioned in protocol and out-of-scope; not given its own section. Evidence base is thinner than CBT and overlaps it substantially.
• Neurofeedback, tDCS, dietary interventions (omega-3, elimination diets). Excluded — evidence base does not meet the bar for inclusion, and including would dilute the message that medication is the high-effect intervention.

Rating notes.

• sleep = 0. The condition itself contributes to delayed sleep phase in ~73-78% of cases Bijlenga et al. 2019 and stimulant treatment can worsen sleep onset if dosed late. Net direct effect of identifying-and-treating ADHD on the sleep dimension is not clearly positive — recognising the comorbidity is what helps, but that benefit belongs to the sleep-disorder entries, not this one. Scored 0 honestly.
• beauty_direct / beauty_cumulative = 0. No mechanism.
• controversy = 3, not higher. The core syndrome is well-established; the contested territory is at the diagnostic edge (telehealth chains, expanded DSM-5 adult criteria, "late-onset adult ADHD" claims). The article reflects this — endorses the science, criticises the edge.
• action = decide, not do. Treatment requires clinician evaluation, ongoing prescribing, and controlled-substance monitoring. Not a reader-implementable intervention.

Future-link candidates. Once the catalogue grows: sleep apnea (often the actual cause when ADHD-like symptoms appear in adults with no childhood history), delayed sleep phase syndrome, executive-function scaffolding systems (calendar architecture, body-doubling), autism spectrum in adults, childhood ADHD, stimulant cardiovascular monitoring protocols, ADHD-specific CBT.

Separate-entry candidates flagged. Childhood ADHD; sleep apnea as a differential for adult-onset attention complaints.

Hard call. Whether to cite specific telehealth-chain names (Cerebral, Done, Klarity). Decided against — the situation is jurisdiction-specific and changing fast; the article describes the failure mode in general terms instead.